Lv11
10 积分 2025-04-08 加入
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
34分钟前
待确认
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
7个月前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
10个月前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
10个月前
已完结
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
1年前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
1年前
已完结
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1年前
已完结
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
1年前
已完结
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
1年前
已关闭
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1年前
已完结
皖公网安备34019202002308
